PMID: 42456707

Efficacy and safety of zalfermin co-administered with semaglutide in participants with fibrosis and cirrhosis due to metabolic dysfunction-associated steatohepatitis: a phase 2, dose-ranging, double-blind, randomised controlled trial.

Loomba Rohit, George Jacob, Castera Laurent, Francque Sven, Lawitz Eric, Shoeb Ahsan, Clausen Jesper Ole, Andersen Birgitte, Larsen Anna Bille, Gluud Lise Lotte

The lancet. Gastroenterology & hepatology · 2026

Vol. 11, Issue 9, pp. 797-811

This entry links to third-party literature. For research use only.